To date, there is no established way to determine in advance if a drug can induce liver injury in the long term. Genetic risk scoring for drug-induced liver injury (DILI) can directly benefit patients by determining their susceptibility to particular drugs. According to an international group of researchers, predicting susceptibility to DILI may lead to increased safety and effectiveness of drug trials. The team developed the risk ranking by re-analyzing numerous loci in genome-wide association studies (GWAS). They identified a list of gene variants that could predict the susceptibility of the liver in response to different compounds.
The team developed an algorithm that integrated the data using various statistical weighting methods. More than 20,000 gene variants were tested in this process. The test combines genetic data and predicts the score. Drug metabolism in the liver,…
